Literature DB >> 18042793

Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

John M Pagel1, Nathan Hedin, Lacey Drouet, Brent L Wood, Anastasia Pantelias, Yukang Lin, Donald K Hamlin, D Scott Wilbur, Ajay K Gopal, Damian Green, Frederick R Appelbaum, Oliver W Press.   

Abstract

We describe the use of pretargeted radioimmunotherapy (PRIT) using an anti-murine CD45 antibody-streptavidin (SA) conjugate followed by radiobiotin to deliver radiation selectively to murine hematolymphoid tissues, which may potentially augment the efficacy and decrease the toxicity of radioimmunotherapy for disseminated murine leukemia. Biodistribution and therapeutic results demonstrated high target organ to nontarget organ ratios of radioactivity and significant long-term survival in leukemic mice using PRIT. These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18042793      PMCID： PMC2234059          DOI： 10.1182/blood-2007-06-097451

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  41 in total

1.  Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens.

Authors:  R A Clift; C D Buckner; F R Appelbaum; E Bryant; S I Bearman; F B Petersen; L D Fisher; C Anasetti; P Beatty; W I Bensinger
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

Review 2.  Allogeneic hematopoietic stem cell transplantation for acute leukemia.

Authors:  F R Appelbaum
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

3.  Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.

Authors:  G Paganelli; P Magnani; F Zito; E Villa; F Sudati; L Lopalco; C Rossetti; M Malcovati; F Chiolerio; E Seccamani
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

4.  Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model.

Authors:  R H van der Jagt; C C Badger; F R Appelbaum; O W Press; D C Matthews; J F Eary; K A Krohn; I D Bernstein
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

5.  Regulation of CD45 expression in human leukemia cells.

Authors:  R Taetle; H Ostergaard; M Smedsrud; I Trowbridge
Journal:  Leukemia       Date:  1991-04       Impact factor: 11.528

6.  Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.

Authors:  D C Matthews; F R Appelbaum; J F Eary; D R Fisher; L D Durack; S A Bush; T E Hui; P J Martin; D Mitchell; O W Press
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

7.  Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML.

Authors:  K Dunussi-Joannopoulos; H J Weinstein; P W Nickerson; T B Strom; S J Burakoff; J M Croop; R J Arceci
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

8.  The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.

Authors:  F R Appelbaum; D C Matthews; J F Eary; C C Badger; M Kellogg; O W Press; P J Martin; D R Fisher; W B Nelp; E D Thomas
Journal:  Transplantation       Date:  1992-11       Impact factor: 4.939

9.  Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.

Authors:  M Juweid; R M Sharkey; A Markowitz; T Behr; L C Swayne; R Dunn; H J Hansen; J Shevitz; S O Leung; A D Rubin
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

10.  Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.

Authors:  J G Jurcic; P C Caron; T K Nikula; E B Papadopoulos; R D Finn; O A Gansow; W H Miller; M W Geerlings; R P Warrell; S M Larson
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701
View more
  19 in total

1.  A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

Authors:  Robert M Sharkey; Oliver W Press; David M Goldenberg
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

2.  Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Authors:  Raya Mawad; Ted A Gooley; Joseph G Rajendran; Darrell R Fisher; Ajay K Gopal; Andrew T Shields; Brenda M Sandmaier; Mohamed L Sorror; Hans Joachim Deeg; Rainer Storb; Damian J Green; David G Maloney; Frederick R Appelbaum; Oliver W Press; John M Pagel
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-20       Impact factor: 5.742

3.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

4.  In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

Authors:  Ethan R Balkin; Aimee Kenoyer; Johnnie J Orozco; Alexandra Hernandez; Mazyar Shadman; Darrell R Fisher; Damian J Green; Mark D Hylarides; Oliver W Press; D Scott Wilbur; John M Pagel
Journal:  Cancer Res       Date:  2014-09-26       Impact factor: 12.701

5.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Authors:  John M Pagel; Aimee L Kenoyer; Tom Bäck; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Steven I Park; Shani Frayo; Amanda Axtman; Nural Orgun; Johnnie Orozco; Jaideep Shenoi; Yukang Lin; Ajay K Gopal; Damian J Green; Frederick R Appelbaum; Oliver W Press
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

6.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

Review 7.  Cancer stem cells: relevance to SCT.

Authors:  T Lin; R J Jones; W Matsui
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

8.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

Authors:  Damian J Green; John M Pagel; Eneida R Nemecek; Yukang Lin; Aimee Kenoyer; Anastasia Pantelias; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Joseph G Rajendran; Ajay K Gopal; Steven I Park; Oliver W Press
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

9.  Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Authors:  Johnnie J Orozco; Aimee Kenoyer; Ethan R Balkin; Ted A Gooley; Donald K Hamlin; D Scott Wilbur; Mark D Hylarides; Sofia H L Frost; Raya Mawad; Paul O'Donnell; Brenda M Sandmaier; Ephraim J Fuchs; Leo Luznik; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

10.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Authors:  Johnnie J Orozco; Tom Bäck; Aimee Kenoyer; Ethan R Balkin; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Shani L Frayo; Mark D Hylarides; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.